The Lectin Pathway in Thrombotic Conditions—A Systematic Review

Julie Brogaard Larsen1 Christine Lodberg Hvas2 Anne-Mette Hvas1,3

1Centre for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
2Department of Anaesthesiology and Intensive Care Medicine, Randers Regional Hospital, Randers, Denmark
3Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Address for correspondence Anne-Mette Hvas, MD, PhD, Department of Clinical Biochemistry, Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Aarhus University, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark (e-mail: am.hvas@dadlnet.dk).


Abstract

The lectin pathway of the complement system can activate the coagulation system in vitro, but the role of the lectin pathway in haemostatic activation and thrombosis in vivo is not clear. We performed a systematic review of the existing literature on associations between the lectin pathway and arterial and venous thrombosis, in accordance with the Assessing the Methodological Quality of Systematic Reviews guidelines. PubMed and Embase were searched from January 1990 to March 2017. We included original studies on human study populations investigating associations between the lectin pathway (protein serum levels, genotype or gene expression) and thrombotic conditions or laboratory coagulation markers. Exclusion criteria were case studies including fewer than five cases, conference abstracts or any other language than English. In total, 43 studies were included which investigated associations between the lectin pathway and cardiovascular thrombotic events (CVEs) (n = 22), ischaemic stroke (n = 9), CVE and stroke (n = 1) and other conditions (systemic lupus erythematosus [n = 6], sepsis-related coagulopathy [n = 3], pulmonary embolism [n = 1], asparaginase treatment [n = 1]). Studies on the lectin pathway and CVE risk reported discrepant results, as both high and low mannose-binding lectin (MBL) serum levels were found to correlate with increased CVE risk. In ischaemic stroke patients, occurrence of stroke as well as increased stroke severity and poor outcome were consistently associated with high serum MBL. For other thromboembolic conditions, only few studies were identified. In conclusion, lectin pathway activation may negatively influence outcome after ischaemic stroke and possibly contribute to CVE risk. Further research is warranted to elucidate the role of the lectin pathway in other thrombotic conditions.

Keywords
► lectin pathway
► complement proteins
► mannose-binding lectin
► thromboembolism
► blood coagulation

Introduction

Interplay between the immune system and haemostasis has long been recognized,1,2 and in recent years, interactions between the complement and coagulation systems have arisen as a field of considerable interest.3 The lectin pathway of the complement system is a relatively new player in this field, but increasing amounts of evidence support a crosstalk between lectin pathway proteins and coagulation, at least in vitro.4 Investigating these interactions more closely may improve our understanding of the pathogenesis of thrombosis in conditions with increased immunologic activation.
The Lectin Pathway
The lectin pathway consists of the pattern recognition molecules mannose-binding lectin (MBL), ficolin-1, -2 and -3 (also named M-ficolin, L-ficolin and H-ficolin) and collectins liver-1 and kidney-1 (CL-L1 and CL-K1), which circulate in complex with the MBL-associated serine proteases (MASP)-1, -2 and -3. The activation of this pathway has been described in detail elsewhere.\(^5,6\) Briefly, the pattern recognition molecules bind to specific carbohydrate structures on microbial and cell surfaces, and this leads to MASP-1 and -2 activation and subsequent cleavage of C4 and C2, assembly of a C3 convertase and activation of the common complement pathway (Fig. 1). Besides, two other proteins, MAP44 (or MAP1) and MAP19 (or sMAP), bind to the pattern recognition molecules and are thought to exert a regulatory role in the lectin pathway.\(^7\) Activation of the lectin pathway contributes to the inflammatory response through activation of the common complement pathway and C5a generation.\(^8\) MBL and ficolins also directly

---

**Fig. 1** Lectin pathway activation. Lectin pathway activation is initiated by recognition of carbohydrate structures by the pattern-recognition molecules like (PRMs) mannose-binding lectin (MBL), ficolins 1–3 and collectin liver-1 (CL-L1) and kidney-1 (CL-K1), which circulate in complex with the MBL-associated serine proteases (MASPs). The binding activates MASPs and causes the subsequent cleaving of complement factors (C) 2 and 4. This generates the split products C2b and C4b, which aggregate to form the C3 convertase complex. Cleavage of C3 further leads to the generation of C5 convertase (C4b2aC3b complex), C5b production and formation of the terminal membrane attack complex on the surface of the microbe or cell. Dark arrows denote enzymatic activity; dashed arrows denote assembly of split products into active complexes.
interact with C-reactive protein and pentraxin-3, contributing to pathogen opsonization and stimulating a pro-inflammatory cytokine response. Moderate increases in lectin pathway protein serum concentrations have been described during the acute phase response, although these findings contrast to some degree.

**Associations between Lectin Pathway Protein Levels and Disease**

Serum levels of lectin pathway proteins show considerable inter-individual variation, particularly the MBL. The genetic background for this variation, as well as possible associations between low serum levels and increased susceptibility to disease, have been investigated during the years. Some polymorphisms are consistently associated with either higher or lower serum protein levels and with increased disease risk, while such associations are less clear for other polymorphisms. 

Table 1 provides an overview of the most commonly described lectin pathway gene polymorphisms and of some clinical conditions associated with lower or deficient lectin pathway protein levels.

Around 10% of the general population have low serum MBL levels. The clinical importance of this is still discussed; but it is well established that MBL deficiency is a risk factor for infection in susceptible populations. However, the exact role of serum MBL levels in infection and the

### Table 1: Associations between lectin pathway gene polymorphisms, serum concentrations and disease risk

<table>
<thead>
<tr>
<th>Protein Corresponding gene</th>
<th>Known mutations or polymorphisms leading to altered serum concentration or function</th>
<th>Diseases or increased risk of disease associated with lower or deficient serum concentration or function</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBL (MBL2)</td>
<td>Lower serum levels: Promoter -550; “H” (wild-type) or “L” (G -&gt; C) allele Promoter -221; “V” (wild-type) or “X” (G -&gt; C) allele 5-untranslated region +4; “P” or “Q” allele (C -&gt; T) Exon 1 (wild-type allele denoted “A”): p.Arg52Cys (“D” allele), p.Gly54Asp (“B” allele), p.Gly57Glu (“C” allele)</td>
<td>Deficiency: Bronchiectasia and increased infection risk in vulnerable populations, e.g. neonates and chemotherapy-treated patients. Worse outcome in pneumonia. Increased risk of spontaneous recurrent abortion.</td>
</tr>
<tr>
<td>MASP-2 and MAp19, MAP2</td>
<td>Lower levels: p.Asp120Gly, p.Pro126Leu, His155Arg, Val237Ala, Arg439His, dupCys-His, Asn-His in c.466 (reviewed by Beltrame et al¹⁴⁵)</td>
<td>Association with disease uncertainty.</td>
</tr>
</tbody>
</table>

Abbreviations: MAp19, MBL-associated protein of 19 kD; MAp44, MBL-associated protein of 44 kD; MASP, MBL-associated protease; MBL, mannose-binding lectin.

Note: 3MC syndrome: Mingarelli, Malpuech, Michels and Carnevale syndrome, characterized by craniofacial abnormalities, developmental delay and intellectual disability.
development of sepsis is not completely understood, as reviewed recently by Charachfieh et al. Only few cases of ficolin28-30 and MASP-2/Map19 deficiency31,32 have been described, while CL-L1 and CL-K1 and MASP-1/-3 deficiency is consistently associated with a developmental syndrome (the 3MC syndrome).33-35 indicating a role for lectin pathway proteins in embryonal development. Besides decreased resistance towards infection in patients with low lectin pathway protein serum levels, there is also a growing interest for the contribution of the lectin pathway to other inflammatory conditions, and for associations between higher serum levels and disease risk. This includes autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE). Associations between MBL and disease severity36 and mortality37 in rheumatoid arthritis are described, and Ammitzboll et al found increased levels of M-ficolin in synovial fluid in rheumatoid arthritis.38 However, a recent meta-analysis found no association between MBL2 genotype and occurrence of rheumatoid arthritis.39 Higher levels of lectin pathway proteins were recently demonstrated in SLE patients,40 and ficolin-1 was associated with disease severity in SLE.41 More recently, the lectin pathway has also been associated with metabolic diseases with inflammatory components, such as diabetes42,43 and atherosclerosis,44,45 and some studies also reported increased levels of serum MBL in cancer.46-48 Thus, there is evidence that the lectin pathway may be involved not only in defence against pathogens but in a broad range of clinical conditions.

**Associations between Lectin Pathway Proteins and Coagulation**

Several studies have investigated associations between the lectin pathway and coagulation in vitro. An overview is presented in **Table 2** and **Fig. 2**. MASP-1 and -2 show affinity for a range of substrates, and MASP-1 shares similarities with prothrombin and MASP-2 with coagulation factor (F)X.49-51 Recombinant (r) active MASP-1 can cleave fibrinogen, demonstrated by the generation of fibrinopeptides A and B and fibrin γ2- and α chains,52,53 and activate FXIII.54 Thus, MASP-1 induces fibrin formation and cross-linking in vitro. Furthermore, Hess et al also found that rMASP-1 generated active thrombin-activatable fibrinolysis inhibitor and prolonged clot lysis time in a plasma-based assay.55 This indicates that MASP-1 also attenuates fibrinolysis. Also, serum-derived MBL-MASP complexes were found to cleave fibrinogen and activate FXIII.55 Recently, it was demonstrated that MASP-1 also cleaves prothrombin and gives rise to what appeared to be active thrombin.56 MASP-1 shortened thromboelastography clotting time and clot formation time in healthy whole blood and plasma57 as well as clot formation time in a micro-vascular flow model under shear stress,58 while MASP-1 inhibition in the same flow model delayed the time to clot formation.58 The ability to cleave prothrombin and generate active thrombin has also been demonstrated for rMASP-2 and MBL-MASP-2 complexes.59 Notably, for both MASP-1 and MASP-2, cleavage of coagulation proteins and clot formation happened at a lower rate than FXa- and/or thrombin-induced cleavage,52,59 and MASP-1- and thrombin-induced clots were also found to differ in density and structure.53 There is evidence that the coagulation system can activate the lectin pathway in turn. Endo et al demonstrated that murine ficolin and MBLS bind to fibrinogen and fibrin, and that fibrinogen induces lectin pathway activation in mouse serum.60 Kozarcanin et al showed that ficolins are capable of binding to the surface of activated platelets, and that fibrin binds MASP-s and induce MASP-C1-inhibitor or MASP-anti-thrombin complex formation, indicating MASP activation.61 Finally, Keizer et al found that tissue factor pathway inhibitor, an endogenous inhibitor of coagulation, can bind and inhibit MASP-2 activation.62 Thus, crosstalk between the lectin pathway and coagulation occurs at several points, and interactions between lectin pathway proteins and coagulation could contribute to hypercoagulability and increased thrombosis risk in a range of clinical conditions. Our aim was to systematically review the existing literature on associations between the lectin pathway and thrombotic conditions in humans.

**Materials and Methods**

The present systematic review was conducted in accordance with the Assessing the Methodological Quality of Systematic Reviews guidelines.63 The protocol was published in the PROSPERO database (reg. no. CRD42017070207, www.crd.york.ac.uk/prospero).

**Literature Search**

PubMed and Embase were searched from 1 January 1990 to 29 March 2017. No additional filters were set. Free-text as well as MeSH terms/Emtree-preferred terms were used. Keywords and search combinations were as follows:

**PubMed**

(“Complement Pathway, Mannose-Binding Lectin[Mesh]” OR “Mannose-Binding Lectin[Mesh]” OR “Mannose-Binding Protein-Associated Serine Proteases[Mesh]” OR “ficolin” [Supplementary Concept] OR “lectin pathway” OR “lectin pathway activation”) OR “mannose-binding lectin”) OR “mannan-binding lectin”) OR “mannose-binding lectin associated serine protease”) OR “mannose-binding lectin associated serine proteases”) OR “map19”) OR “map44”) OR “collectin 11”) OR “collectin 10”) OR “ficolin”) AND (((((((((((“Emboli and Thrombosis” [Mesh]) OR “Myocardial Ischemia”[Mesh]) OR “Stroke”[Mesh]) OR “Mesenteric Vascular Occlusion”[Mesh]) OR “Renal Artery Occlusion”[Mesh]) OR “Peripheral Arterial Disease”[Mesh]) OR “Disseminated Intravascular Coagulation”[Mesh]) OR (“Blood Coagulation”[Mesh]) OR “Platelet Activation”[Mesh]) OR “blood coagulation”) OR “platelet activation”) OR “arterial thrombosis”) OR “venous thrombosis”) OR “venous thromboembolism”) OR “disseminated intravascular coagulation”) OR “myocardial infarction”) OR “cardiovascular disease”) OR “ischemic stroke”) OR “hemorrhagic stroke”) OR “renal artery thrombosis” OR

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
## Table 2 Overview of studies investigating associations between the lectin pathway and coagulation in vitro

<table>
<thead>
<tr>
<th>Author, year</th>
<th>LP protein</th>
<th>Research question addressed</th>
<th>Coagulation protein or activation assay</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jenny et al 2018</td>
<td>rMASP-1</td>
<td>Influence of MASP-1 and inhibition of MASP-1 on blood clot formation</td>
<td>Whole blood, micro-vascular flow model</td>
<td>MASP-1 addition accelerates clot formation while inhibition of MASP-1 prolongs time to clot formation</td>
</tr>
<tr>
<td>Kozarczin et al 2016</td>
<td>MASP-1 and -2, ficolins, MBL</td>
<td>Ability of coagulation factors and platelets to activate MASPs</td>
<td>Platelets, fibrin LP-platelet binding assessed with flow cytometry</td>
<td>Activated platelets bind ficolin-1, -2 and -3 on surface. Fibrin and fibrin d-dimer bind MASP-1 and -2 and induce MASP-C1inh/-anti-thrombin complex formation</td>
</tr>
<tr>
<td>Jenny et al 2015</td>
<td>rMASP-1</td>
<td>Influence of MASP-1 addition on blood clotting</td>
<td>Thromboelastography; whole blood, platelet-poor plasma, purified fibrinogen solution</td>
<td>MASP-1 addition shortens thromboelastography clotting time and clot formation time in the presence of prothrombin</td>
</tr>
<tr>
<td>Jenny et al 2015</td>
<td>rMASP-1</td>
<td>Ability of MASP-1 to cleave wild-type or mutant prothrombin; characterization of cleavage sites and products</td>
<td>Prothrombin (wild-type or mutant at cleaving sites R271, R320, R393)</td>
<td>MASP-1 cleaves prothrombin at R271 and R393 and gives rise to active thrombin species</td>
</tr>
<tr>
<td>Keizer et al 2015</td>
<td>rMASP-2; LP activation (C4 deposition)</td>
<td>Ability of TFPI to inhibit MASP-2; characterization of inhibitory domain</td>
<td>Tissue factor pathway inhibitor (TFPI)</td>
<td>TFPI (Kunitz-2 domain) inhibits MASP-2 activity (chromogenic assay) and human serum LP activation</td>
</tr>
<tr>
<td>Hess et al 2012</td>
<td>rMASP-1</td>
<td>Ability of MASP-1 to activate coagulation and inhibit fibrinolysis</td>
<td>Clot formation and lysis assay, prothrombin fragment 1 + 2, fibrinopeptide A, thrombin-activatable fibrinolysis inhibitor, FXIII activation</td>
<td>MASP-1 activates FXIII, induces generation of prothrombin fragment 1 + 2 and fibrinopeptide A, activates thrombin-activatable fibrinolysis inhibitor and prolongs clot lysis</td>
</tr>
<tr>
<td>Endo et al 2010</td>
<td>rFicolin A, rMBL-A, rMBL-C (mouse) LP activation (C4 deposition)</td>
<td>Ability of fibrinogen/fibrin to bind ficolin and MBL and to activate LP</td>
<td>Fibrinogen and fibrin (human)</td>
<td>Murine ficolin and MBL binds to fibrinogen (Aα and Bβ chains) and fibrin (αα and ββ chains) in dose-dependent manner. Fibrinogen induces LP activation in mouse serum</td>
</tr>
<tr>
<td>Skjoedt et al (conference abstract)</td>
<td>MAp44</td>
<td>Ability of MAp44 to inhibit platelet function and coagulation</td>
<td>Platelet activation and aggregation, whole blood clotting, fibrin clot formation and lysis in plasma (human)</td>
<td>MAp44 attenuates platelet activation and aggregation, clot amplitude in whole blood (intrinsic pathway) and fibrin clot formation</td>
</tr>
<tr>
<td>Gulla et al 2010</td>
<td>Ficolin- or MBL-MASP-1/-2 complexes (serum-derived)</td>
<td>Ability of ficolin- or MBL-MASP complexes to activate coagulation</td>
<td>Fibrin clot formation in citrated plasma and purified fibrinogen/FXIII solution (human)</td>
<td>Ficolin- or MBL-MASP complexes induces FXIII activation and fibrinogen cleavage in purified systems and clot formation in plasma</td>
</tr>
<tr>
<td>Krarup et al 2008</td>
<td>rMASP-1</td>
<td>Ability of MASP-1 to cleave coagulation proteins</td>
<td>Fibrinogen, FXIII (human)</td>
<td>MASP-1 cleaves FXIII (presence of activated A-chain) and fibrinogen (presence of γ-chains and fibrinopeptide B) but at a significantly lower rate than thrombin</td>
</tr>
<tr>
<td>Krarup et al 2007</td>
<td>rMASP-2, rMBL-A-MASP-2 complexes (rat)</td>
<td>Ability of MASP-2 to cleave and activate prothrombin</td>
<td>Prothrombin, thrombin activity (VPR-AMC turnover), fibrin formation (turbidimetry, 125I-labeled fibrin deposition) in purified solutions (human)</td>
<td>rMASP-2 cleaves prothrombin (presence of pre-thrombin and fragment 1) and generates active thrombin, but at a lower rate than FXa</td>
</tr>
<tr>
<td>Hajela et al 2002</td>
<td>rMASP-1</td>
<td>Ability of MASP-1 to cleave fibrinogen</td>
<td>Purified fibrinogen/FXIII (human)</td>
<td>MASP-1 cleaves fibrinogen and induces crosslinking (generation of γ2- and αα'-chains)</td>
</tr>
</tbody>
</table>

Abbreviations: C, complement factor; F, coagulation factor; MAp44, MBL-associated protein of 44 kD; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; r, recombinant.
“mesenteric thrombosis”) OR “hepatic thrombosis”) OR “peripheral artery occlusion”).

Embase
(Mannose binding lectin/exp OR ‘Complement lectin pathway’/exp OR ‘Complement activation’/exp OR ‘Mannan binding lectin associated serine proteinase’/exp OR ‘Ficolin’/exp OR ‘Map19’ OR ‘Map44’ OR ‘Collectin liver 1’) AND (‘Thromboembolism’/exp OR ‘Heart muscle ischemia’/exp OR ‘Heart infarction’/exp OR ‘Brain ischemia’/exp OR ‘Cerebrovascular accident’/exp OR ‘Disseminated intravascular coagulation’/exp OR ‘Blood clotting’).

Other relevant literature was identified by checking the reference lists of recent original studies and reviews and employing the ‘cited-by’ function in Scopus.

Inclusion and Exclusion
The inclusion criteria were: (1) original work, (2) human study population and (3) investigating associations between the lectin pathway and thromboembolic disease or laboratory coagulation parameters (surrogate endpoints for increased thrombosis risk). Both interventional and observational studies, including prospective cohort studies as well as case–control studies, were eligible for inclusion. Accepted endpoints for the lectin pathway were plasma or serum protein levels, genetic polymorphisms, gene expression and activation assays for one or more of the following proteins: MBL, ficolin-1, -2, -3, CL-L1 or -K1, MASP-1, -2, -3, MAp44 and MAp19. Accepted endpoints for thromboembolic disease were both microscopic thrombosis (e.g. disseminated intra-vascular coagulation) and large vessel occlusion, and both arterial and venous thrombosis. We included acute ischaemic stroke and cardiovascular thrombotic events (CVEs) defined as acute coronary syndrome (myocardial infarction [MI] and unstable angina pectoris) but not transient cerebral ischaemia, stable angina pectoris or atherosclerotic lesions without sign of thrombosis. Exclusion criteria were (1) case studies including fewer than five cases, (2) other language than English and (3) conference abstracts.

Fifty abstracts were randomly selected and screened for either exclusion or full-text reading by all three authors, and any disagreement was solved by consensus. The remaining abstracts were screened by J.B.L. In a similar fashion, 20 papers proceeding to full-text reading were randomly selected and read in full by all authors, and any disagreement was again solved by consensus. Inclusion or exclusion of the remaining papers were performed by J.B.L., and in case of doubt, all three authors discussed the study in question.

Data Extraction and Quality Assessment
Data extraction from the included articles was performed by J.B.L. and checked by C.L.H. and A.M.H. Study quality was assessed using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies and the Quality Assessment Tool for Case-Control Studies, National Institutes of Health, USA. The quality assessment tools provide a guide for
systematically assessing the risk of different types of bias in the study and thus the internal validity of the results. The tools comprise a list of items concerning key methodological points and specific criteria to be fulfilled for each item. A numeric rating scale is not employed; instead, each study is rated 'good', 'fair' or 'poor' according to the estimated risk of serious bias (low, intermediate or high), which is based on the number and types of criteria not fulfilled. Quality assessment was performed by all the three authors for all included studies, and disagreement was solved by consensus.

**Data Synthesis**

The included studies were heterogeneous regarding the design, study populations and endpoints, thus a complete meta-analysis of the data was not performed. Forest plots were made for the CVE sub-group to visualize results and support our qualitative data synthesis using Stata 14 (StataCorp, Texas, United States). If data for forest plots could not be extracted from the included article, an attempt to obtain data was made via emails to the corresponding authors.

**Results**

In total, 43 original articles were included in the present review and are presented in -Tables 3-6. The screening and inclusion/exclusion process is displayed in detail in -Fig. 3.

We grouped the studies first according to their major clinical focus and second according to their design. Among

### Table 3

<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design</th>
<th>Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoint(s) for cardiovascular events (CVE)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prospective studies including nested case-control studies (n = 10)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poppelaars et al 66 2016 Rating: Good</td>
<td>Longitudinal</td>
<td>Plasma MBL (EDTA), ELISA</td>
<td>Patients: end-stage kidney disease on haemodialysis (n = 107) Mean follow-up: 27 months Censored if received transplantation Age: 63 ± 16 years Gender (M/F, %): 66/34</td>
<td>(1) Cardiac events (CE) alone: MI, UAP, CABG or PCI (2) CVE: MI, UAP, CABG, PCI, ischaemic stroke or claudication (3) All-cause mortality</td>
<td>↑ CE and ↑ CVE associated with ↓ MBL (adjusted HR = 3.96 [1.49–10.54] for CE and 3.98 [1.88–8.42] for CVE) MBL not associated with MI, PCI, CABG or sudden cardiac death (HR not reported) MBL improved prediction of CVE (Harrell’s C = 0.76 vs. 0.73, p = 0.01 in a model with vs. without MBL)</td>
</tr>
<tr>
<td>Siezenga et al 67 2011 Rating: Good</td>
<td>Longitudinal</td>
<td>MBL2 genotype</td>
<td>Patients: type 2 diabetes (n = 134) Mean follow-up: 7.7 years Age: 51 ± 11 years Gender (M/F, %): 46/54 Ethnicity: South Asian</td>
<td>MI, PCI, CABG or sudden cardiac death</td>
<td>↑ CVE in low versus intermediate/high genotype (HR = 3.43 [1.24–9.49]) CVE not associated with serum MBL (HR = 0.93 [0.50–1.73])</td>
</tr>
<tr>
<td>Troelsen et al 37 2010 Rating: Fair</td>
<td>Longitudinal</td>
<td>MBL2 genotype Promoter -221, codon 52, 54, 57 Serum MBL, ELISA</td>
<td>Patients: rheumatoid arthritis (n = 229) Mean follow-up: 10.3 years Gender (M/F, %): 18/82</td>
<td>(1) CVE-related mortality (2) All-cause mortality</td>
<td>↑ CVE-related and overall mortality associated with high versus intermediate/low genotype (adjusted HR = 2.0 [1.0–4.1] for CVE-related and 1.7 [1.1–2.8] for overall) ↑ CVE and overall mortality associated with ↑ serum MBL (adjusted HR = 1.3 [1.0–1.5] for CVE and 1.2 [1.0–1.3] for overall)</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design</th>
<th>Study population</th>
<th>Endpoint(s) for cardiovascular events (CVE)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prospective studies including nested case–control studies (n = 10)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Troelsen et al<sup>68</sup> 2007<sup>a</sup>  
Rating: Good | Longitudinal  
*MBL2* genotype  
Promoter –221, codon 52, 54, 57  
Serum MBL, ELISA | Patients: rheumatoid arthritis (*n* = 229)  
Mean follow-up: 9.5 years  
Gender (M/F, %): 18/82 | (1) MI  
(2) CVE-related mortality | † CVE in high versus intermediate/low genotype (adjusted HR = 5.0 [1.4–17.5] for MI and 4.1 [1.2–14.3] for mortality)  
† CVE associated with † serum MBL (adjusted HR = 6.3 [2.0–20.1] for MI and 10.5 [2.7–41.3] for mortality) |
| Berger et al<sup>69</sup> 2007  
Rating: Fair | Longitudinal  
*MBL2* genotype  
Codon 52, 54, 57  
Serum MBL, ELISA | Patients: pancreas-kidney transplant recipients  
(genotype, *n* = 97; serum MBL, *n* = 99)  
Follow-up: 12 years  
High/low MBL: Age: 40 ± 8/41 ± 7 years  
Gender (M/F, %): 68/32 and 61/39 | (1) CVE-related mortality  
(2) Overall mortality | † CVE mortality associated with † serum MBL (0/34 deaths vs. 11/65 deaths, *p* = 0.01)  
† overall mortality associated with † serum MBL (adjusted HR = 4.4 [1.30–15.10])  
Mortality not associated with genotype in multivariate analysis (HR not reported) |
| Keller et al<sup>70</sup> 2006  
Rating: Good | Nested case–control  
Serum MBL, ELISA | Patients: CVE during follow-up (*n* = 781)  
Controls matched for age, gender, date of visit (± 3 months) and duration of follow-up (*n* = 1,505)  
Mean follow-up: 6 years  
Cases/controls:  
Age: Men 65 ± 8/64 ± 8, years; women 67 ± 7/67 ± 7 years  
Gender (M/F, %): 62/38 and 64/36 | MI or CVE-related mortality | In men: † CVE associated with † MBL (adjusted OR = 1.55 [1.08–2.22] in highest vs. lowest MBL quartile)  
In women: no association between MBL and CVE (adjusted OR = 0.98 [0.61–1.56]) |
| Saevarsdottir et al<sup>71</sup> 2005  
Rating: Good | Nested case–control  
Serum MBL, ELISA | Patients: CVE during follow-up (*n* = 867)  
Controls (*n* = 442), matching not reported  
Mean follow-up: 27 years  
Cases/controls:  
Age: 56 (51–62) years  
55 (50–61) years  
Gender (M/F, %): 58/42 and 50/50 | MI or CVE-related mortality | Overall: No association between CVE and MBL (OR = 0.88 [0.69–1.1]  
† CVE associated with † MBL in patients with diabetes (OR = 0.15 [0.03–0.78]) and hypercholesterolaemia (OR = 0.26 [0.10–0.64]) |
| Hertle et al<sup>45</sup> 2016  
Rating: Fair | Longitudinal  
*MBL2* genotype  
Codon 52, 57  
Plasma MBL (EDTA), | Healthy or diabetic subjects (*n* = 495); Type 2 diabetes or impaired glucose | MI, ischaemic stroke,  
CABG or PCI during follow-up | No associations between LP and CVE  
*MBL2* genotype: OR = 1.60 [0.73–3.51] |
### Table 3 (Continued)

<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design, Lectin pathway parameters, Laboratory methods</th>
<th>Study population</th>
<th>Endpoint(s) for cardiovascular events (CVE)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prospective studies including nested case–control studies (n = 10)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vengen et al\textsuperscript{72} 2012 Rating: Good</td>
<td>MASP-1, -2, -3, MAp44 (citrate), ELISA</td>
<td></td>
<td></td>
<td>MASPs, MAp44: ORs not reported</td>
</tr>
<tr>
<td></td>
<td>Nested case–control MBL2 genotype, Promoter -221, codon 52, 54, 57, FCN1 promoter -542 SNP, FCN2 exon 8 +6359 and +6424, FCN3 +1637 SNP</td>
<td>Follow-up: 12 years, MI during follow-up (n = 370) Controls matched for age and gender (n = 370) Mean follow-up: 12 years, MI, Controls</td>
<td></td>
<td>MI,</td>
</tr>
<tr>
<td></td>
<td>Nested case–control Serum ficolin-1, -2, -3, MASP-3, MAp44, ELISA</td>
<td>Mean follow-up: 12 years, MI during follow-up (n = 370) Controls matched for age and gender (n = 370) Mean follow-up: 12 years, MI, Controls</td>
<td></td>
<td>MI,</td>
</tr>
<tr>
<td><strong>Cross-sectional and case–control studies (n = 4)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pesonen et al\textsuperscript{74} 2009 Rating: Fair</td>
<td>Case–control MBL2 genotype, Promoter -550 and -221, codon 52, 54, 57, Serum MBL, ELISA</td>
<td>Patients: UAP (n = 113) or MI (n = 241) Controls: healthy volunteers matched for age, gender and parish (n = 334) Cases: Age: 63 years Gender (M/F, %): 78/22</td>
<td></td>
<td>(1) UAP MI, (2) MI</td>
</tr>
<tr>
<td>Hansen et al\textsuperscript{75} 2004 Rating: Fair</td>
<td>Case–control MBL2 genotype, Promoter -550 and -221, UTR +4, codon 52, 54, 57, Serum MBL, TRIFMA</td>
<td>Patients: type 1 diabetes and nephropathy (n = 199) or normoalbuminuria (n = 192) matched for age, gender and duration of diabetes Controls: healthy volunteers matched for age (n = 100) Cases: Age: 41 ± 10 years Gender (M/F, %): 61/39 Ethnicity: Caucasian</td>
<td></td>
<td>MI, stroke or claudication</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoint(s) for cardiovascular events (CVE)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frauenknecht et al(^{25}) 2013 Rating: Fair</td>
<td>Case–control Plasma MASP-1, -2, -3 or MAp44 (citrate), TRIFMA</td>
<td>Patients: MI ((n = 49)) Controls: healthy volunteers ((n = 50)) and patients with stable CAD ((n = 104)) Patients: Age: 57 ± 9 years Gender ((M/F, %)): 80/20</td>
<td>MI</td>
<td>(\uparrow) MASP-1 and (\downarrow) MASP-2 in MI compared with controls ((\text{MASP-1}: 11.93 \text{ vs. } 9.44 \mu\text{g/mL, } p &lt; 0.001; \text{MASP-2}: 369.8 \text{ vs. } 442.9 \text{ ng/mL, } p = 0.005)) (\rightarrow) MASP-3 or MAp44 between groups ((p &gt; 0.05))</td>
</tr>
<tr>
<td>Zhang et al(^{76}) 2013 Rating: Fair</td>
<td>Case–control Plasma MASP-2 (anti-coagulant not reported), ELISA</td>
<td>Patients: MI ((n = 29)) Controls: healthy volunteers ((n = 50)); patients with stable CAD ((n = 27)) Patients: Age: 61 (32–72) years Gender ((M/F, %)): 69/31 Ethnicity: African American 59%, Caucasian 10%, Hispanic 31%</td>
<td>MI</td>
<td>(\downarrow) MASP-2 in MI versus healthy or CAD controls ((235 \text{ vs. } 460 \text{ [healthy] and } 471 \text{ ng/mL [CAD], } p &lt; 0.01))</td>
</tr>
</tbody>
</table>

Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary artery disease; CPB, cardiopulmonary bypass; CVE, cardiovascular event; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; FCN, gene encoding ficolin; HR, hazard ratio; LP, lectin pathway; MAp44, MBL-associated protein of 44 kDa \((\text{also known as MAP1})\); MASP, MBL-associated protease; MBL, mannose-binding lectin; MBL2, gene encoding MBL; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SNP, single-nucleotide polymorphism; STEMI, ST-segment elevation myocardial infarction; TRIFMA, time-resolved immunofluorometric assay; UAP, unstable angina pectoris.

Notes: Study population: Age, gender and ethnicity are stated if reported in the study. Age is rounded to whole years and indicated by mean ± standard deviation or median (interquartiles) unless otherwise specified. Results: Numbers in parentheses after OR/HR are 95% confidence intervals unless otherwise specified.

\(^{a}\)Same study population as Troelsen et al 2010.\(^{37}\)
\(^{b}\)Same study population as Venge et al 2012.\(^{72}\)

The included studies, 22 focused on CVE, predominantly MI,\(^{37,45,66–85}\) 9 on ischaemic stroke,\(^{86–94}\) 1 on both CVE and stroke\(^{95}\) and 11 on other conditions \((\text{SLE, } n = 6, \text{CAD, } n = 6, \text{other, } n = 3)\).\(^{41,61,96–99}\) Disseminated intravascular coagulation \((\text{DIC, } n = 3, \text{102,103,105})\); pulmonary embolism, \(n = 1\);\(^{100}\) and \(L\)-asparaginase-treated pediatric patients, \(n = 1\).\(^{101}\)

Out of 23 CVE studies, 16 investigated associations between the lectin pathway and occurrence of CVE,\(^{37,45,66–76,83,84,95}\) while 9 of the 23 prospectively investigated associations between the lectin pathway and outcome \((\text{e.g. mortality or recurrent MI})\) in patients with \(\text{existing CVE.}^{77–85}\) Among the 10 studies on ischaemic stroke, 8 investigated associations between lectin pathway proteins and occurrence of stroke \((\text{case–control design).}^{86–92,99}\) and 6 of the 10 studies investigated associations between lectin pathway proteins and stroke severity and/or functional outcome in existing stroke \((\text{prospective or cross-sectional design).}^{88–90,92–94}\)

The majority of studies \((n = 33)\) included MBL serum/plasma levels and/or \(MBL2\) genotype, while nine studies investigated one or more MASP\(_{S}\),\(^{45,61,73,76,83,84,92–95}\) seven studies one or more ficolins,\(^{41,72,73,83,86,88,92}\) five studies \(\text{MAp44}^{15,73,83,84,95}\) and one investigated \(\text{CL-K1.}\(^{102}\)

Studies including \(MBL2\) genotype all investigated polymorphisms in codon 52, 54 and 57 in exon 1,\(^{37,45,66–79,72,74,75,77,80,94,96–99,103}\) Additionally, some included one or more of three polymorphisms in the promoter or 5’ untranslated region\(^{37,68,72,74,75,77,80,94,97,99}\) (please refer to \(\text{Table 1}\)). All studies classified the patients’ genotypes or haplotypes after their known association with MBL expression and serum levels. Thus, genotype was classified overall as ‘high’ \((\text{wild-type}), ‘\text{intermediate}\) or ‘low’ in these studies, and this classification is used throughout the text and tables of the present review.

The overall study quality was moderate to high, with 22 \((51\%)\) rating ‘good’, 17 \((40\%)\) rating ‘fair’ and 4 \((9\%)\) rating ‘poor’. The individual ratings are provided in \(\text{Tables 3–6}\).

Below, we summarize the findings of the included studies on associations between the lectin pathway and thrombotic events.

Continued
Table 4  Studies investigating associations between the lectin pathway and disease severity or outcome in existing cardiovascular disease

<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design</th>
<th>Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoints for disease severity or outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mellbin et al77 2010 Rating: Good</td>
<td>Longitudinal, baseline blood sampling shortly after MI diagnosis MBL2 genotype Promoter -221, codon 52, 54, 57 Serum MBL, TRIFMA</td>
<td>Patients: type 2 diabetes and MI (n = 387 serum only and n = 287 serum and genotype) Mean follow-up: 2.5 years Age: 70 (61–77) years Gender (M/F, %): 68/32</td>
<td>Recurrent MI, ischaemic stroke or CVE-related mortality</td>
<td>No association between CVE and serum MBL or genotype (HR = 0.93 [0.85–1.01])</td>
<td></td>
</tr>
<tr>
<td>Trendelenburg et al78 2010 Rating: Good</td>
<td>Longitudinal, baseline blood sampling before PCI Serum MBL, ELISA</td>
<td>Patients: STEMI, undergoing primary PCI (n = 890) Follow-up: 90 days Low/high MBL Age: 60 (53–73) years /60 (51–70) years Gender (M/F, %): 76/42 and 79/21</td>
<td>(1) All-cause mortality (2) Cardiac dysfunction: Composite endpoint of death, cardiogenic shock or heart failure</td>
<td>↓ MBL associated with ↓ all-cause mortality (HR = 0.14 [0.02–1.02], p = 0.02) but not with cardiac dysfunction (HR = 0.89 [0.52–1.53])</td>
<td></td>
</tr>
<tr>
<td>Haahr-Pedersen et al79 2009 Rating: Good</td>
<td>Longitudinal, baseline blood sampling before PCI Plasma MBL (EDTA), TRIFMA</td>
<td>Patients: STEMI, undergoing primary PCI (n = 74) Follow-up: 48 hours Ejection fraction &gt; 35%/&lt; 35% Age: 62 years58/63 (59–68) years Gender (M/F, %): 79/21 and 81/19</td>
<td>Cardiac dysfunction: left ventricle ejection fraction &lt; 35%</td>
<td>Cardiac dysfunction associated with ↓ MBL (adjusted OR = 5.5 [1.5–19.3])</td>
<td></td>
</tr>
<tr>
<td>Collard et al80 2007 Rating: Good</td>
<td>Longitudinal MBL2 genotype Promoter -550 and 221, UTR +4, codon 52, 54, 57</td>
<td>Patients undergoing first-time isolated CABG (n = 843) Follow-up: 3 days post-operation MI/no MI Age: 64 ± 11 years /65 ± 10 years Gender (M/F, %): 74/26 and 79/21 Ethnicity: Caucasian</td>
<td>Post-operative MI</td>
<td>The combination of a 5’ and a 3’ haplotype encoding serum MBL was associated with ↓ MI (adjusted OR = 4.72 [1.41–15.85]) No association found between any haplotype alone and MI (ORs not reported)</td>
<td></td>
</tr>
<tr>
<td>Ueland et al81 2006 Rating: Fair</td>
<td>Longitudinal, blood sampling at study enrolment and after 1 month Plasma MBL (EDTA), ELISA</td>
<td>Patients: MI and ↓ left ventricle ejection fraction (n = 234) Mean follow-up: 2.7 years Low/high MBL: Age: 68 ± 10 years /67 ± 10 years Gender (M/F, %): 63/37 and 74/26</td>
<td>(1) Recurrent MI (2) Overall mortality</td>
<td>↑ recurrent MI at 1 mo associated with ↓ MBL (adjusted HR = 2.3 [1.2–4.5] to 2.7 [1.4–5.2] depending on the model used) No association between MBL and overall mortality (OR not reported)</td>
<td></td>
</tr>
<tr>
<td>Limnell et al82 2002 Rating: Poor</td>
<td>Retrospective, blood sampling at the end of follow-up Serum MBL, ELISA</td>
<td>Patients undergoing CABG with one or more venous graft (n = 62) Median follow-up: 1.3 years Age: 56 (43–67) years Gender: all male</td>
<td>Graft occlusion</td>
<td>↑ graft occlusion associated with ↓ MBL (adjusted OR = 11.5 [1.24–106])</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Cardiovascular Events

The Lectin Pathway and Occurrence of Cardiovascular Events

Studies investigating the lectin pathway and CVE occurrence are presented in Table 3. The following endpoints for CVE were investigated: MI, unstable angina pectoris, STEMI, recurrent MI, ischaemic stroke, CVE-related mortality, all-cause mortality, myocardial revascularization procedure (coronary artery bypass grafting [CABG] or percutaneous coronary intervention [PCI]), or a composite endpoint consisting of two or more of these. Some studies investigated the association between the lectin pathway and CVE in patients with other clinical conditions such as diabetes mellitus.

Table 4 (Continued)

<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoints for disease severity or outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schoos et al\textsuperscript{83} 2013 Rating: Fair</td>
<td>(1) Case–control: MI occurrence (2) Longitudinal: Cardiac function after MI Blood sampling at day 1, 4, 7 and 31 after MI Controls: reference intervals in healthy individuals Follow-up: 6 months Low/high ficollin-2: Age: 59 (51–63) years /54 (50–62) years Gender (M/F, %): 76/24 and 82/18</td>
<td>Patients: MI undergoing primary PCI (n = 35) Controls: reference intervals in healthy individuals Follow-up: 6 months Low/high MASP-2: Age: 56 (49–66) years /60 (50–70) years Gender (M/F, %): 76/24 and 82/18</td>
<td>↓ ficollin-2 in MI patients versus controls (day 1: 870 vs. 3,370 ng/mL, p not reported) ↓ in MBL, ficollin-3 or MAP44 in MI versus controls, p not reported ↓ ficollin-2 alone associated with ↓ end-diastolic volume and ↓ end-systolic volume at baseline but not 6 mo (p = 0.004 and &lt; 0.001) A combination of ↓ ficollin-2 and ↓ MBL or ↓ MAP44 was associated with ↓ EDV and ESV from baseline to 6 mo (p = 0.006 and p = 0.052)</td>
<td></td>
</tr>
<tr>
<td>Holt et al\textsuperscript{84} 2014 Rating: Fair</td>
<td>(1) Case–control: MI occurrence (2) Longitudinal: Salvaged myocardium Blood sample before PCI Plasma MASP-1,-3 or MAP44 (EDTA), TRIFMA Controls: Healthy blood donors (n = 140) Follow-up: 30 days Age: 63 (56–72) years Gender (M/F, %): 77/23</td>
<td>Patients: MI (n = 122) undergoing PCI Controls: Healthy blood donors (n = 140) Follow-up: 30 days Age: 63 (56–72) years Gender (M/F, %): 77/23</td>
<td>Salvage index calculated from myocardial area at risk estimated before PCI and final infarct size (1) ↓ MASP-1, MASP-3 and MAP44 in MI compared with controls (p: &lt; 0.001–0.002) (2) No correlation between LP proteins and salvage index or area at risk (Spearman’s ρ: −0.12 to 0.02, all p &gt; 0.12)</td>
<td></td>
</tr>
<tr>
<td>Mellbin et al\textsuperscript{85} 2012* Rating: Good</td>
<td>Longitudinal, blood sample at study enrolment and 3 months Plasma MASP-2 (anticoagulant not reported), TRIFMA Patients: type 2 diabetes and MI (n = 397) Mean follow-up: 2.4 years Age: 70 (61–77) years Gender (M/F, %): 68/32</td>
<td>Controls: Healthy blood donors (n = 140) Follow-up: 30 days Age: 63 (56–72) years Gender (M/F, %): 77/23</td>
<td>CVE: recurrent MI, ischaemic stroke or CVE-related death No association between MASP-2 at admission or 3 mo and CVE (HR = 0.86 [0.62–1.20])</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary artery disease; CPB, cardiopulmonary bypass; CVE, cardiovascular event; EDTA, ethylenediaminetetraacetic acid; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; FCN, gene encoding ficollin; HR, hazard ratio; LP, lectin pathway; MASP, MBL-associated protease; MBL, mannose-binding lectin; MBL2, gene encoding MBL; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; STEMI, ST-segment elevation myocardial infarction; TRIFMA, time-resolved immunofluorometric assay; UAP, unstable angina pectoris.

Note: Study population: Age, gender and ethnicity are stated if reported in the study. Age is rounded to whole years and indicated by mean ± standard deviation or median (interquartiles) unless otherwise specified. Results: Numbers in parentheses after OR/HR are 95% confidence intervals unless otherwise specified.

*Same study population as Mellbin et al 2010.\textsuperscript{77}
<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoints for stroke severity or outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kouchaki et al&lt;sup&gt;86&lt;/sup&gt; 2017 Rating: Good</td>
<td>Cross-sectional, blood sampling at admission Serum ficolin-1, ELISA</td>
<td>Patients ($n = 82$) Age: 70 ± 14 years Gender (M/F, %): 51/49</td>
<td>NIHSS at admission</td>
<td>↑ ficolin-1 correlated moderately with ↑ NIHSS (multivariate analysis, $\beta = 0.73$, $p &lt; 0.001$)</td>
</tr>
<tr>
<td>Huang et al&lt;sup&gt;87&lt;/sup&gt; 2016 Rating: Good</td>
<td>Case–control, blood sampling on the morning after admission Serum MBL, TRIFMA</td>
<td>Patients ($n = 175$) Controls: healthy volunteers matched for age and gender ($n = 175$) Age: 68 (57–75) years Gender (M/F, %): 56/44</td>
<td>(1) Stroke occurrence (2) NIHSS at admission (all) (3) Infarct size ($n = 134$)</td>
<td>↑ MBL associated with stroke occurrence: Area under ROC curve $= 0.76$ (0.71–0.83) MBL correlated moderately with NIHSS score ($r = 0.70$, $p &lt; 0.0001$) and weakly with infarct size ($r = 0.49$, $p &lt; 0.001$)</td>
</tr>
<tr>
<td>Zangari et al&lt;sup&gt;88&lt;/sup&gt; 2016 Rating: Fair</td>
<td>(1) Case–control: Stroke occurrence (2) Longitudinal: Severity and outcome after stroke Blood sampling at 6 h after admission (cohort 1) or 48 h, 4 d and 1 mo after admission (cohort 2) Plasma MBL, ficolin-1, -2, -3 (EDTA), ELISA</td>
<td>Patients ($n = 165$) Two cohorts; different blood sampling times but same inclusion/exclusion criteria (cohort 1, $n = 80$, cohort 2, $n = 85$) Controls: next-of-kin’s to cases, matched on age and gender ($n = 61$) Follow-up: 3 months Cohort 1/cohort 2: Age &gt; 50: 94% years /86% years Gender (M/F, %): 41/59 and 58/42 Caucasian: 100% and 96%</td>
<td>(1) Stroke occurrence (2) NIHSS at admission (3) Modified Rankin Scale</td>
<td>↓ ficolin-1 and -3 associated with stroke: Area under ROC curve $= 0.91$ for ficolin-1 and 0.68 for ficolin-3 at 6 hour (95% CIs not reported) Ficolin-1 at 6 h improved prediction of outcome (area under ROC $= 0.93$ [0.87–0.98] vs. 0.87 [0.77–0.96] for NIHSS + age alone) Unfavourable outcome associated with ↓ ficolin-1 at 6 h (adjusted OR $= 2.21$ [1.11–4.39]) but not ficolin-3 (OR $= 0.99$ [0.93–1.05]) or other LP proteins (all $p &gt; 0.05$) No association between LP and initial stroke severity (data not shown)</td>
</tr>
<tr>
<td>Song et al&lt;sup&gt;89&lt;/sup&gt; 2015 Rating: Good</td>
<td>(1) Case–control: Stroke occurrence (2) Longitudinal: Outcome after stroke Blood sampling at first morning after admission Serum MBL, TRIFMA</td>
<td>Patients with type 2 diabetes ($n = 188$) Controls: healthy volunteers, matched for age and gender ($n = 100$) Follow-up: 1 year Age: 68 (57–79) years Gender (M/F, %): 56/44 Ethnicity: all Chinese</td>
<td>(1) Stroke occurrence (2) NIHSS at admission (3) Modified Rankin Scale (4) All-cause mortality</td>
<td>Unfavourable outcome associated with ↑ MBL (adjusted OR $= 8.99$ [2.21–30.12], area under ROC curve $= 0.75$ [0.68–0.83]) ↑ mortality associated with ↑ MBL (adjusted OR $= 13.22$ [2.05–41.21], area under ROC curve $= 0.85$ [0.80–0.90]) MBL correlated moderately with NIHSS score (Spearman, $r = 0.71$, $p = 0.009$)</td>
</tr>
<tr>
<td>Author, year, rating</td>
<td>Design Lectin pathway parameters</td>
<td>Study population</td>
<td>Endpoints for stroke severity or outcome</td>
<td>Results</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Zhang et al&lt;sup&gt;90&lt;/sup&gt; 2015 Rating: Good</td>
<td>(1) Case–control: Stroke occurrence (2) Longitudinal: Outcome after stroke</td>
<td>Patients (n = 231) Controls: healthy volunteers matched for age and gender (n = 100) Follow-up: 90 days (n = 222 completed follow-up) Good/poor outcome: Age: 61 (55–73) years /69 (61–76) years Gender (M/F, %): 62/38 and 60/40 Ethnicity: all Chinese</td>
<td>(1) Stroke occurrence (2) NIHSS at admission (3) Modified Rankin Scale (4) All-cause mortality</td>
<td>Unfavourable outcome associated with ↑ MBL (adjusted OR = 5.28 [2.88–10.67]) ↑ mortality associated with ↑ MBL (adjusted OR = 6.99 [3.55–13.97]) MBL correlated weakly with NIHSS score ( r = 0.33, p &lt; 0.001 )</td>
</tr>
<tr>
<td>Wang et al&lt;sup&gt;91&lt;/sup&gt; 2014 Rating: Fair</td>
<td>Case–control, blood sampling at first morning after admission</td>
<td>Patients (n = 148) Controls: healthy volunteers, matched for age and gender (n = 100) Cases: Age: 68 (59–75) years Gender (M/F, %): 54/46 Ethnicity: all Chinese</td>
<td>(1) NIHSS at admission (all) (2) Infarct size (n = 112)</td>
<td>↑ MBL in stroke versus controls (1.332 vs. 678 μg/L, multiple logistic regression OR = 1.002 [1.001–1.008]) ↑ MBL correlated weakly with stroke severity (Spearman, ( r = 0.61, p = 0.004 )) ↑ MBL with ↑ infarct size (ANOVA, ( p &lt; 0.0001 )) Area under ROC curve = 0.76 (0.70–0.82)</td>
</tr>
<tr>
<td>Frauenknecht et al&lt;sup&gt;93&lt;/sup&gt; 2013 Rating: Fair</td>
<td>Case–control Plasma- MASP-1, -2, -3, MAP44 (citrate), TRIFMA</td>
<td>Patients (n = 66) Controls: healthy volunteers (n = 50) and patients with stable coronary artery disease (n = 104) Stroke patients: Age: 65 ± 16 years Gender (M/F, %): 62/38</td>
<td>Stroke occurrence</td>
<td>↓ MASP-2 in stroke compared with controls. --- MASP-1, MASP-3 or MAP44 between groups ( (p &gt; 0.05) )</td>
</tr>
<tr>
<td>Füst et al&lt;sup&gt;92&lt;/sup&gt; 2011 Rating: Poor</td>
<td>(1) Case–control: Stroke occurrence (2) Longitudinal: Outcome after stroke</td>
<td>Patients (n = 65) Controls: patients with stable carotid artery stenosis (n = 135) and healthy volunteers (n = 100) Follow-up: until discharge Age: 70 ± 10 years Gender (M/F, %): 51/49</td>
<td>(1) NIHSS at admission, good (&lt; 16) versus poor (≥16) (2) Modified Rankin Scale at discharge</td>
<td>Unfavourable outcome associated with ↓ ficolin-3 at day 3 (OR = 5.63 [1.50–21.15]) No difference in mean ficolin-2 between outcome groups, ( p = 0.30 ), OR not computed Poor NIHSS associated with ↓ ficolin-3 at day 3 ( (p = 0.02) ), but not at admission No association between NIHSS and ficolin-2 ( (p = 0.30) )</td>
</tr>
<tr>
<td>Osthoff et al&lt;sup&gt;93&lt;/sup&gt; 2011 Rating: Good</td>
<td>Longitudinal, blood sampling at admission</td>
<td>Patients receiving either conservative treatment (n = 287) or thrombolysis (n = 66)</td>
<td>(1) Stroke severity: NIHSS at admission (all), infarct size (in 199 patients) (2) Modified Rankin</td>
<td>Conservative treatment group: Unfavourable outcome associated with ↑ MBL:</td>
</tr>
</tbody>
</table>
hypercholesterolaemia, rheumatoid arthritis, end-stage kidney disease or pancreas-kidney transplantation. Thus, the study populations were heterogeneous, and we summarize their main findings here with this limitation in mind.

Overall, the reported associations between MBL and CVE occurrence varied considerably between studies with regards to effect size as well as direction. Two case–control studies found that CVE occurrence was associated with increased MBL serum levels and high genotype. This was supported by prospective studies, which all reported increased CVE occurrence in patients with high serum MBL levels or high genotype, however, Keller et al only found this association in a sub-population of men. In contrast to this increased CVE risk related to high MBL, three studies reported that CVE was associated with low MBL, although Saevardsdottir et al only found this association in sub-groups with hypercholesterolaemia and diabetes. It was possible to extract / obtain data from six studies investigating serum MBL and five studies investigating MBL2 genotype to perform forest plots of crude or adjusted odds ratios for CVE with high serum MBL or high genotype (Fig. 4). The forest plots support that high serum MBL or genotype was not consistently associated with a higher CVE risk in the included studies.

Regarding other lectin pathway proteins, no clear patterns emerged. Two studies reported higher MASP-1 levels in patients with MI versus healthy controls, two studies found lower MASP-2 levels in patients with MI versus healthy controls; and finally, two studies reported associations between MI and higher MASP-3 levels. Vengen et al also found MI to be associated with higher ficolin-2

### Table 5 (Continued)

<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoints for stroke severity or outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervera et al 2010</td>
<td>Longitudinal MBL2 genotype Promoter -221, codon 52, 54, 57 MASP2 SNP D120G Serum MBL, MASP-2, ELISA</td>
<td>Patients with ischaemic (n = 109) or haemorrhagic (n = 26) stroke Follow-up: 90 days Low/high MBL: Age: 74 ± 13 years /73 ± 12 years Gender (M/F, %): 38/62 and 53/47</td>
<td>Favourable versus unfavourable outcome, ‘favourable’ defined as modified Rankin Scale &lt; 2, NIHSS score &lt; 2 and Barthel Index ≥95%</td>
<td>Unfavourable outcome associated with ↑ serum MBL (adjusted OR = 1.29 [1.02–1.69]) and high genotype (adjusted OR = 10.85 [1.87–62.94]) No association between MASP2 polymorphism and outcome (OR = 0.92 [0.23–3.73])</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; CT, computed tomography; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; LP, lectin pathway; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; MBL2, gene encoding MBL; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; ROC, receiver operator characteristics; TRIFMA, time-resolved immunofluorometric assay; WHO, World Health Organization.

Note: Study population: ‘Patients’ refer to patients with ischaemic stroke (cases) unless otherwise specified. Stroke was verified with CT/MRI or according to the WHO criteria for all studies. Age, gender and ethnicity are stated if reported in the study. Age is rounded to whole years and indicated by mean ± standard deviation or median (interquartiles) unless otherwise specified. Endpoints: All studies defined ‘favourable’ outcome as Rankin Scale < 2 points or Barthel Index ≥95%. Results: Numbers in parentheses after OR/HR/area under ROC curve are 95% confidence intervals unless otherwise specified.
<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoints for thromboembolic disease or coagulation activity</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systemic lupus erythematosus (SLE)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kozarcanin et al61 2016 Rating: Fair</td>
<td>Cross-sectional MASP-1/-2 activation (MASP-1/-2 in complex with C1-inhibitor or anti-thrombin)</td>
<td>Patients: SLE (n = 69), multi-trauma(n = 10) Trauma: Age: 23–80 years Gender (M/F, %): 80/20</td>
<td>SLE: Platelet activation markers, platelet count, FXIa, FXIIa Trauma: Platelet count, PT, aPTT, TAT-complex and fibrinogen</td>
<td>SLE: Positive correlation between MASP complexes and platelet activation, FXIa and FXIIa (rho values, 0.31–0.74, all ( p &lt; 0.001 )) Trauma: Positive correlation between MASP complexes and PT, TAT-complex and fibrinogen, but not aPTT or platelet count</td>
</tr>
<tr>
<td>Hein et al41 2015 Rating: Poor</td>
<td>Cross-sectional Plasma ficolin-1, -2, -3 (EDTA), ELISA</td>
<td>Patients: SLE (n = 68) Age: 40 (range: 21–76) years Gender (M/F, %): 9/91</td>
<td>History of arterial or venous thrombosis</td>
<td>↑ ficolin-1 in patients with a history of arterial thrombosis (( p = 0.005 )) No difference in ficolin-2 or -3 for arterial thrombosis and no difference for venous thrombosis (all ( p &gt; 0.05 ))</td>
</tr>
<tr>
<td>Jönsen et al96 2007 Rating: Good</td>
<td>Longitudinal MBL2 genotype Promoter -550, -221, codon 52, 54, 57</td>
<td>Patients: SLE (n = 143) Mean follow-up: 15 years Age at enrolment not reported Gender (M/F, %): 12/88</td>
<td>Cerebrovascular, coronary or peripheral vascular event</td>
<td>No association between MBL2 genotype and thrombotic events (adjusted OR = 3.3 [0.80–14])</td>
</tr>
<tr>
<td>Font et al97 2007 Rating: Fair</td>
<td>Cross-sectional MBL2 genotype Promoter -550, -221, UTR +4, codon 52, 54, 57</td>
<td>Patients: SLE (n = 415) Age: 41 ± 1 years Gender (M/F, %): 7/93</td>
<td>Previous cerebrovascular thrombosis (arterial or venous), MI, intra-abdominal artery thrombosis, DVT or PE</td>
<td>No association between MBL2 genotype and thrombotic events in multivariate analysis (OR not reported)</td>
</tr>
<tr>
<td>Calvo-Alén et al98 2006 Rating: Fair</td>
<td>Longitudinal MBL2 genotype Codon 52, 54, 57</td>
<td>Patients: SLE (n = 415) Mean follow-up: 3.9 years Thrombosis: yes/no Age: 44 ± 15 years /36 ± 12 years Gender (M/F, %): 17/83 and 9/91 Ethnicity: Hispanic: 23% and 30% African: 40% and 40% Caucasian: 37% / 30%</td>
<td>MI, angina pectoris, CABG, ischaemic stroke, transient ischaemic attack or peripheral vascular disease</td>
<td>No significant association between MBL2 genotype and thrombotic events, except cerebrovascular events alone: ↑ events in low versus intermediate/high genotype (( p = 0.049 ))</td>
</tr>
<tr>
<td>Øhlenschlaeger et al99 2004 Rating: Good</td>
<td>Longitudinal MBL2 genotype Promoter -550, -221, codon 52, 54, 57</td>
<td>Patients: SLE (n = 91) Mean follow-up: 11 years Gender (M/F, %): 10/90 Ethnicity: Caucasian</td>
<td>MI, cerebrovascular event, peripheral vascular disease, DVT or PE</td>
<td>↑ arterial events in patients with low versus intermediate/high genotype (adjusted HR = 7.0 [1.9–25.4]) No association between genotype and venous thrombosis (data not shown)</td>
</tr>
</tbody>
</table>
## Table 6 (Continued)

<table>
<thead>
<tr>
<th>Author, year, rating</th>
<th>Design Lectin pathway parameters</th>
<th>Study population</th>
<th>Endpoints for thromboembolic disease or coagulation activity</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disseminated intravascular coagulation (DIC)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Sprong et al\textsuperscript{103} 2009  
Rating: Fair |
| Cross-sectional  
*MBL2* genotype  
Codon 52, 54, 57 |
| Patients: septic shock  
(*n* = 18)  
Age: 6 months–7 years  
Gender (M/F, %): 50/50 |
| Platelet count, fibrinogen, ISTH DIC score |

| Zhao et al\textsuperscript{104} 2015  
Rating: Good |
| (1) Cross-sectional: DIC at admission  
(2) Longitudinal: DIC development after admission  
Blood sampling at admission  
Serum *MBL*, ELISA |
| Patients: sepsis with/without shock  
(*n* = 267)  
Follow-up: until discharge  
DIC/no DIC at admission:  
Age: 67 ± 15 years  
/68 ± 14 years  
Gender (M/F, %): 61/39 and 60/40 |
| Overt DIC (ISTH DIC score ≥5) at admission or developed during hospitalization, assessed once daily |

| Takahashi et al\textsuperscript{102} 2014  
Rating: Good |
| Case–control  
Plasma CL-K1 (citrate), ELISA |
| Patients: DIC of different aetiology  
(*n* = 549)  
Controls: Patients without DIC (*n* = 82) and healthy controls (*n* = 27)  
DIC/no DIC:  
Age: 67 (53–78) years  
/64 (51–73) years  
Gender (M/F, %): 56/44 and 60/40  
Ethnicity: Caucasian |
| DIC: biphasic aPTT waveform present |

| Others |
|----------------------|---------------------------------|------------------|-------------------------------------------------------------|---------|
| Lv et al\textsuperscript{100} 2013  
Rating: Poor |
| Case–control  
LP mRNA expression (whole genome expression) |
| Patients: PE (*n* = 20)  
Controls: patients without PE matched for age and gender (*n* = 20)  
Cases:  
Age: 70 ± 14 y  
Gender (M/F, %): 55/45 |
| PE |

| Merlen et al\textsuperscript{101} 2015  
Rating: Fair |
| Longitudinal, blood sampling before therapy and every 3 wk until end of therapy  
Serum *MBL*, ELISA |
| Patients: acute lymphoblastic leukaemia receiving L-asparaginase (*n* = 97)  
Follow-up: 25 wk  
Age: 6.4 (range: 1–17) years  
Gender (M/F, %): 56/44 |
| Plasma-fibrinogen and anti-thrombin |

Abbreviations: aPTT, activated partial thromboplastin time; CABG, coronary artery bypass grafting; CL-K1, collectin kidney 1; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; EIA, enzyme immunoassay; F, coagulation factor; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; LP, lectin pathway; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; MBL2, gene encoding MBL; MI, myocardial infarction; mRNA, messenger ribonucleic acid; OR, odds ratio; PE, pulmonary embolism; PT, prothrombin time; SLE, systemic lupus erythematosus; ROC, receiver operator characteristics; TAT, thrombin-anti-thrombin.

Note: Study population: Age, gender and ethnicity are stated if reported in the study. Age is rounded to whole years and indicated by mean ± standard deviation or median (interquartiles) unless otherwise specified. Results: Numbers in parentheses after OR/HR/area under ROC curve are 95% confidence intervals unless otherwise specified.
levels, while Schoos et al reported the opposite. No associations between ficolin-1 or -3 and CVE were observed.

Four studies analysed MAp44, of which three found no association between this protein and CVE, while one study reported increased MAp44 levels in MI patients versus healthy controls.

The Lectin Pathway and Outcome in Existing Cardiovascular Disease

The nine studies investigating the association between lectin pathway proteins and outcome in patients with pre-existing CVE are presented in Table 4. All studies included study populations with recent MI, most having undergone either CABG or PCI in the early phase of the study. The following
endpoints for outcome or severity of CVE were investigated: recurrent MI,\textsuperscript{80,81} reduced left ventricle ejection fraction (heart failure),\textsuperscript{79,83} change in end-systolic/-diastolic volume,\textsuperscript{83} infarct size,\textsuperscript{83} myocardial salvage index,\textsuperscript{84} early CABG venous graft occlusion,\textsuperscript{82} CVE-related mortality, all-cause mortality\textsuperscript{81} or a composite endpoint consisting of two or more of these.\textsuperscript{77,78,85}

Three studies reported that low serum MBL or low genotype was associated with a better outcome after MI.\textsuperscript{78–80} In contrast, two studies found an association between low MBL and early recurrent MI\textsuperscript{81} or graft occlusion after CABG,\textsuperscript{82} while Mellbin et al found no association between MBL or MASP-2 and CVE.\textsuperscript{77,85} Holt et al investigated MASP-1, MASP-3 and MAp44 and found no association between either of these proteins and myocardial salvage after PCI.\textsuperscript{84} Schoos et al demonstrated no association between MAp44 alone and cardiac function either, but reported that both high ficolin-2 alone and a combination of high ficolin and low MAp44 were associated with impaired cardiac function (higher end-systolic and end-diastolic volumes).\textsuperscript{83}

Ischaemic Stroke

The Lectin Pathway and Occurrence of Ischaemic Stroke

Eight case–control studies investigated lectin pathway patients with ischaemic stroke versus healthy controls.\textsuperscript{86–92,95} In general, stroke was diagnosed according to valid diagnostic criteria and/or verified with radiological imaging. Among the five studies analysing MBL, four studies reported higher serum MBL levels in stroke patients compared with healthy controls.\textsuperscript{87,89–91} High MBL was moderately associated with the occurrence of stroke with areas under the receiver operator characteristics (ROC) curves = 0.76.\textsuperscript{87,91} In contrast, one study found no association between plasma MBL and ischaemic stroke.\textsuperscript{88}
Zangari et al found lower levels of ficolin-1, -2 and -3 during the early phase of stroke and a strong association between low ficolin-1 at 6 hours and stroke occurrence (area under the ROC curve = 0.91). This was in accordance with Füst et al who also reported low ficolin-2 and -3 levels at admission in stroke patients. Frauenknecht et al found lower levels of MASP-2 in stroke patients compared with controls, but demonstrated no difference for MASP-1, -3 or MAP44.

The Lectin Pathway and Functional Outcome or Severity of Stroke
The following endpoints were used for stroke severity and functional outcome after stroke: initial stroke severity assessed with National Institute of Health Stroke Scale (NIHSS) where increasing score indicates increasing stroke severity, infarct volume estimated with magnetic resonance imaging, functional outcome assessed with modified Rankin Scale or Barthel Index or a composite endpoint of NIHSS, modified Rankin Scale and Barthel Index. A favourable outcome on the Rankin Scale was typically defined as < 2 points and on the Barthel Index as > 95%.

In general, the studies demonstrated an association between high MBL and increased stroke severity and unfavourable outcome. MBL was reported to correlate positively with NIHSS (though only weakly to moderately) and with infarct size. Several studies found that high MBL was independently associated with both higher mortality and unfavourable outcome on Rankin Scale and Barthel Index. The only study investigating MBL2 genotype supported these findings, reporting that both high serum MBL and high genotype was associated with an unfavourable outcome. Song et al calculated the ability of MBL to predict mortality and functional outcome, finding moderate areas under the ROC curves (0.85 for mortality and 0.75 for Rankin Scale). Only one study did not find an association between MBL and stroke severity or functional outcome.

With regards to other lectin pathway proteins, Kouchaki et al found a significant positive correlation between ficolin-1 and NIHSS score, indicating that high ficolin-1 levels are associated with more severe stroke. This contrasted with Zangari et al who found no association between ficolins and NIHSS score, but reported an association between low ficolin-1 and unfavourable outcome on modified Rankin Scale. Füst et al found that low ficolin-3 at day 3 after stroke was associated with unfavourable outcome, but also with less initial stroke severity.

Other Conditions
Systemic Lupus Erythematosus
Four studies examined associations between MBL2 genotypes and thrombotic events in SLE patients. Öhlenschlaeger et al reported that low genotype was associated with increased risk of arterial thrombosis, defined as cardiovascular, cerebrovascular or peripheral vascular events, but not with venous thrombosis. The three remaining studies found no independent association or only a borderline significant association between MBL2 genotype and thrombotic events.

Hein et al reported that SLE patients with a history of arterial but not venous thrombosis had significantly higher circulating ficolin-1 levels. The method for verifying a previous thrombotic event was not reported, nor could it be found in the original source cited. Kozarcanin et al did not include clinical endpoints, but investigated correlations between MASP-1 and -2 activation and platelet and coagulation parameters in SLE patients and multi-trauma patients. The authors reported that MASP activation correlated significantly with activation of both primary and secondary haemostasis in both patient groups.

Disseminated Intravascular Coagulation
Sprong et al investigated the association between MBL2 genotype and coagulation parameters and clinical manifestations indicating DIC in children with meningococcal disease and septic shock. Children with low genotype (n = 2 of 18) had a lower DIC score, and their platelet counts and fibrinogen levels were markedly closer to the normal range compared with children with intermediate or high genotype. Due to the small number of patients, statistical significance was not calculated. In a study on adult sepsis patients, Zhao et al reported higher MBL levels in patients with overt DIC at admission and in patients who developed DIC later compared with patients without DIC, but MBL was not found to be an independent predictor for the development of DIC. In both the DIC and non-DIC group, the mean MBL serum level was well below the range reported by other authors in healthy individuals, and the difference between the DIC and non-DIC group, although statistically significant, was subtle. Finally, Takahashi et al investigated CL-K1 in 549 patients with DIC of various aetiologies and found that DIC was associated with higher CL-K1 levels.

Other Studies
Lv et al conducted a case–control study in patients with pulmonary embolism and healthy controls and extensively investigated complement-related messenger ribonucleic acid (mRNA) expression. They found lower expression of MBL2 and MASP2 mRNA in patients with pulmonary embolism compared with healthy controls.

Finally, Merlen et al investigated serum–MBL, fibrinogen, anti-thrombin and thrombotic events in paediatric patients who were treated with L-asparaginase, a chemotherapeutic drug with a known pro-thrombotic effect. The main finding related to the scope of the present review was that MBL correlated positively, although only weakly, with both fibrinogen and anti-thrombin.

Discussion
The present systematic review did not reveal a consistent association between the lectin pathway and thrombotic conditions. MBL serum levels and/or genotype were the most commonly investigated lectin pathway parameters.
An association between MBL and CVE occurrence or outcome was observed in several studies but differed in both effect size and direction. In ischaemic stroke patients, high serum MBL was consistently associated with occurrence of stroke as well as increased stroke severity and unfavourable outcome. Only few studies on other thrombotic conditions were identified.

In general, the included studies were of high quality, with 90% rating ‘good’ or ‘fair’ using the National Institute of Health quality assessment tools. This indicates a low risk of bias and overall high validity of the results. Among the 43 studies, 29 (67%) were prospectively designed, while the rest was cross-sectional or case–control studies. CVE (n = 23), ischaemic stroke (n = 10), SLE-associated thrombosis (n = 6) and sepsis-associated DIC (n = 3) were the most commonly investigated thrombotic conditions. Almost all studies had clinical thromboembolic disease as their main outcome, and only five studies used laboratory coagulation parameters as endpoints. A variety of materials (serum, ethylenediaminetetraacetic acid plasma, citrated plasma) were used for lectin pathway protein analysis, as well as different assays (enzyme-linked immunosorbent assay, time-resolved immunofluorometric assay); however, there did not seem to be an association between the materials or assays used and the reported results.

As summarized in the introduction, the available in vitro evidence consistently reports that MBL and MASP-1 and -2 can activate the coagulation system. This is supported by animal studies. Studies on induced carotid artery and cerebral thrombosis in murine models found that MBL-deficient mice had preserved carotid blood flow, and less intra-vascular fibrin deposition compared with wild-type mice. Takahashi et al demonstrated a prolonged tail bleeding time in MBL-deficient mice which could be restored with recombinant MBL. Taken together, the available evidence from in vitro and animal studies thus suggests a pro-coagulant effect of lectin pathway activation and a protective role of MBL deficiency on thrombus development.

The results of the present systematic review do not unequivocally support these findings of in vitro and animal studies. The included studies reported conflicting results, especially regarding the role of the lectin pathway in cardiovascular thrombosis. Both high and low MBL levels were reported to be risk factors for CVE, while two large cohort studies found no overall influence of serum MBL on future CVE risk. A probable explanation of these conflicting results could be the diversity in study populations; they all carried an increased CVE risk but differed with regards to the underlying pathophysiology and baseline risk of thrombotic events. Furthermore, follow-up times varied, and a variety of endpoints or combinations of endpoints were employed.

The studies on ischaemic stroke more consistently reported associations between high MBL levels and stroke occurrence as well as severity with a single exception. The ficolins were investigated in three studies only. Associations between both ficolin-1 and ficolin-3 and stroke severity and long-term outcome were described; however, the findings were contrasting, and the scarcity of studies make it difficult to conclude on the role of ficolins in ischaemic stroke. An association between high MBL and unfavourable outcome was also consistently reported after stroke, again with one exception, as recently reviewed by Fumagalli and De Simoni, but this association was not consistently reported after MI. An important point is that the functional outcome after an ischaemic event is not only related to the thrombus itself but also to other factors, among which is ischaemia-reperfusion injury. Interestingly, increasing evidence points to the lectin pathway as a possible player in ischaemia-reperfusion injury, showing that the lectin pathway contributes to the increased inflammation, tissue damage and necrosis in ischaemia-reperfusion injury, together with other mechanisms.

In SLE patients, one well-conducted follow-up study demonstrated that low MBL genotype was associated with higher risk of arterial thrombotic events, but three other studies on SLE patients could not reproduce these findings. Two studies investigated associations between MBL and sepsis-related DIC and both reported higher MBL levels to be associated with more severe coagulation disturbances. However, one study was very small while in the second study, only a discrete difference in MBL levels was observed between the DIC and non-DIC group, and MBL was not found to be an independent predictor of DIC in sepsis. Thus, the influence of the lectin pathway on coagulation and thrombosis risk in both SLE and sepsis remains uncertain.

We included both arterial and venous thrombosis in the present review, with the majority of included studies focusing on arterial thrombotic events. Although arterial and venous thrombosis include several common factors, the mechanisms behind them differ considerably. coronary and cerebral artery thrombosis usually includes a component of atherosclerosis. This is a complex condition characterized by chronic low-grade inflammation with activation of several immune system components, which may have been on-going for a long period of time before the major thrombotic event takes place. Activated platelets are also a key component of atherosclerosis, as they are activated by oxidized LDL and activated endothelial cells in the atherosclerotic plaque. In turn, they activate and uphold inflammation by facilitating monocyte migration, activating neutrophils and secreting pro-inflammatory factors. Interestingly, cholesterol crystals in the atherosclerotic plaque may play a role in activating the lectin pathway directly, and in diabetic patients, altered endothelial
glycosylation patterns may further cause MBL binding and lectin pathway activation.\(^\text{42}\) Venous thrombosis, on the other hand, is driven largely (though not exclusively) by activation of secondary haemostasis, and traditional risk factors are hypercoagulability, loss of endothelial integrity with tissue factor exposure and decreased blood flow or stasis.\(^\text{123}\) Hypercoagulability can be inherited, but one of the major risk factors for venous thrombosis is inflammation, potentially induced by bacterial infection, autoimmune disease and traumatic or surgical acute phase response. The inflammation-induced hypercoagulability is driven by pro-inflammatory cytokines such as interleukin-6 and caused by an increased production of pro-coagulant factors such as tissue factor, fibrinogen, FVIII, von Willebrand factor and plasminogen activator inhibitor-1, as well as decreased production of the endogenous anti-coagulants, anti-thrombin protein C and S.\(^\text{123,124}\) The venous thrombosis is often an acute event in itself, but local inflammatory changes in the vessel can persist and lead to chronic venous disease.\(^\text{125,126}\)

The lectin pathway is an interesting potential contributor to inflammation-driven hypercoagulability and thrombosis through direct activation by MASPs, as described in the introduction. Since there is considerable crosstalk and mutual activation between the coagulation system and the lectin pathway, they may well activate each other in thrombotic and inflammatory conditions and thereby uphold the inflammatory and hyper-coagulable response in a vicious cycle. This emerging concept of immunothrombosis—or thromboinflammation—has recently been discussed.\(^\text{123,127}\) However, it should be noted that since changes in both lectin pathway proteins and coagulation factors occur during the acute phase response, any observed correlation between plasma levels does not equal causation, but may simply indicate that an acute phase reaction is on-going. It should also be considered that although there is solid evidence that MASPs are able to induce clot formation in vitro, this occurs at a lower rate than thrombin-induced clot formation.\(^\text{52}\) Furthermore, MASP-1-induced fibrin cleavage was found to be less dense and with thicker fibres than thrombin-induced clots.\(^\text{53}\) This type of clots has been found more susceptible to lysis.\(^\text{128}\) Thus, the lectin pathway may have not a merely pro-coagulant but also a modulatory effect on coagulation, which could be clinically important.

The strengths of the present review were that we assessed the literature systematically, searching both PubMed and Embase and using broad search terms to minimize the risk of overlooking relevant studies. We performed a formal quality assessment and found the vast majority of studies to be of good or fair quality, which strengthens the validity of their results and our conclusions. The majority of studies included clinical endpoints for thromboembolic disease. However, some limitations should be mentioned. The study populations and endpoints for thrombosis were heterogeneous, and only few studies on thromboembolic conditions other than CVE and stroke were identified. This limits the value of comparison across all the identified studies and makes it impossible to conclude on the significance of the lectin pathway in the development of thrombotic conditions in a broader clinical setting.

To conclude, the existing evidence indicates that lectin pathway activation is associated with poor outcome after ischaemic stroke. Furthermore, there is some evidence for involvement of the lectin pathway in CVEs, although the exact role of the lectin pathway in this setting is not yet fully elucidated. With regards to other thrombotic conditions, only sparse clinical evidence exists, and future studies in this field are warranted.

**Funding**

J.B.L. was supported by a grant from the Faculty of Health, Aarhus University and the Health Research Fund of the Central Denmark Region.

**Conflict of Interest**
None.

**References**

The Lectin Pathway in Thrombotic Conditions

Larsen et al.


76 Zhang M, Hou YJ, Cavanagh E, et al. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int J Cardiol 2013;166(02):499–504


104 Zhao X, Chen YX, Li CS. Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department. J Crit Care 2015;30(02):290-295
106 Takahashi K, Chang WC, Takahashi M, et al. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 2011;216(1-2):96–102
116 La Bonte LR, Dokken B, Davis-Gorman G, Stahl GL, McDonagh PF. The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart. Diab Vasc Dis Res 2009;6(03):172-180


Skjødt M-O, Munthe-Fog L, Hansen KM, Garred P. Inhibition of the coagulation system by the complement regulator MBL/Ficolin-Associated Protein-1 (MAP-1). Molecular Immunology 2014;61(02):219

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.